Avecho inks medicinal cannabis supply deal with Tasmanian Alkaloids
Category: #business  By Mateen Dalal  Date: 2020-04-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Avecho inks medicinal cannabis supply deal with Tasmanian Alkaloids

Avecho Biotechnology, a renowned Australian pharmaceutical company, has reportedly announced a new medical cannabis supply contract with Tasmanian Alkaloids, an Australian biopharmaceutical company, with an aim to boost the company’s natural medicinal cannabis products.

Terms of the new agreement states that Avecho would integrate natural cannabis products that are supplied by the Tasmania-based, Tasmanian Alkaloids, with its TPM (tocopheryl phosphate mixture) technology to study how this technology would boost the oral absorption of natural cannabinoids from the medicinal cannabis-based products.

In order to create oral, injectable, as well as topical products for the overall human health industry, TPM is essentially being developed further. However, it would also be used to improve the health and feed efficiency of livestock.

Meanwhile, Avecho also appointed new Chief Operations Officer, Dr. Roksan Libinaki, and Chief Executive Officer, Dr. Paul Gavin, making substantial changes to their management team. This new duo plans to take the company towards a novel drug development era that enhances existing methods by integrating artificial and natural cannabis extracts.

As per Avecho, the newly appointed executives represents the company’s next phase of development along with the supply deal showcasing a strategy of integrating synthetic and natural cannabis extracts to produce patentable products.

Executive Chairman, Avecho, Dr. Greg Collier stated that with the growth in the use of natural cannabis extracts, lack of differentiation in the cannabis products is becoming apparent. The company’s TPM may provide a unique solution with a patent protection potential, for firms working to differentiate their medicinal cannabis products in a crowded marketplace.

As per Tasmanian Alkaloids, the company is among the top fully integrated exporters and manufacturers of controlled substance extracts, including production and extraction of natural medicinal cannabis.

The newly signed agreement means Tasmanian Alkaloids has agreed to supply certain natural medicinal cannabis products to Avecho for R&D purposes. In return, Avecho would buy the natural medicinal cannabis’ future commercial supplies from Tasmanian Alkaloids, upon the commercialization of  shortlisted products.

 

Source credit: https://smallcaps.com.au/avecho-strikes-medicinal-cannabis-supply-agreement-tasmanian-alkaloids/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Ellipsis Health, Augmedix to offer automated mental health patient screenings
Ellipsis Health, Augmedix to offer automated mental health patient screenings
By Mateen Dalal

AI vocal biomarker technology provider Ellipsis Health has reportedly disclosed a strategic partners...

Enevate, NantG Power partner to develop next-gen ultra-high-performance battery
Enevate, NantG Power partner to develop next-gen ultra-high-performance battery
By Mateen Dalal

A strategic agreement to produce next-generation battery was announced by Enevate and NantG Power, t...

TPG in plans to invest $336M in Denodo for accelerating growth
TPG in plans to invest $336M in Denodo for accelerating growth
By Mateen Dalal

Denodo, a leading data management company, and TPG, a global alternative asset management ...